World's Best Scientists 2026 revealed!
Award Badge
Best Female Scientists
2025
Award Badge
Medicine
France
2023

D-Index & Metrics

Best Female Scientists

D-Index
156
Citations
157959
World Ranking
117
National Ranking
4

Medicine

D-Index
159
Citations
168767
World Ranking
795
National Ranking
20

Research.com Recognitions

  • 2025 - Research.com Best Female Scientists Award
  • 2023 - Research.com Medicine in France Leader Award

Overview

Caroline Robert is affiliated with the University of Paris-Saclay in France. Their research primarily focuses on oncology, molecular biology, and immunology, with specific attention to cancer immunotherapy and biomarker development.

The scientist's recent publications include:

  • A decade of immune-checkpoint inhibitors in cancer therapy, 2020, Nature Communications

Frequent co-authors in their scholarly work include:

  • Paolo A. Ascierto
  • Dirk Schadendorf
  • Georgina V. Long
  • Reinhard Dummer
  • Célèste Lebbe

Caroline Robert has contributed extensively to various publication venues with the highest number of publications in the following journals:

  • Journal of Clinical Oncology (65 publications)
  • European Journal of Cancer (57 publications)
  • Annals of Oncology (48 publications)
  • Annales de Dermatologie et de Vénéréologie - FMC (28 publications)
  • Cancer Research (20 publications)

The scope of their research primarily covers the following fields of study:

  • Medicine
  • Biochemistry, Genetics and Molecular Biology

Subfields of particular focus include:

  • Oncology
  • Molecular Biology
  • Immunology
  • Radiology, Nuclear Medicine and Imaging
  • Pulmonary and Respiratory Medicine

Main research topics associated with Caroline Robert consist of:

  • Cancer Immunotherapy and Biomarkers
  • CAR-T cell therapy research
  • Melanoma and MAPK Pathways
  • Cutaneous Melanoma Detection and Management
  • Immunotherapy and Immune Responses
  • Colorectal Cancer Treatments and Studies
  • Nonmelanoma Skin Cancer Studies

Best Publications

  • Improved Survival with Ipilimumab in Patients with Metastatic Melanoma.

    F. Stephen Hodi;Steven J. O'Day;David F. McDermott;Robert W. Weber

  • Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

    Paul B. Chapman;Axel Hauschild;Caroline Robert;John B. Haanen

  • PD-1 blockade induces responses by inhibiting adaptive immune resistance

    Paul C. Tumeh;Christina L. Harview;Jennifer H. Yearley;I. Peter Shintaku

  • Nivolumab in previously untreated melanoma without BRAF mutation.

    Caroline Robert;Georgina V. Long;Benjamin Brady;Caroline Dutriaux

  • Pembrolizumab versus Ipilimumab in Advanced Melanoma

    Caroline Robert;Caroline Robert;Caroline Robert;Jacob Schachter;Georgina V. Long;Ana Arance

  • Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

    Caroline Robert;Luc Thomas;Igor Bondarenko;Steven O'Day

  • Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

    Omid Hamid;Caroline Robert;Adil Daud;F. Stephen Hodi

  • Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota

    Marie Vétizou;Marie Vétizou;Marie Vétizou;Jonathan M. Pitt;Jonathan M. Pitt;Jonathan M. Pitt;Romain Daillère;Romain Daillère;Romain Daillère;Patricia Lepage

  • Nivolumab and ipilimumab versus ipilimumab in untreated melanoma

    Michael A. Postow;Jason Chesney;Anna C. Pavlick;Caroline Robert

  • Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib

    Caroline Robert;Boguslawa Karaszewska;Jacob Schachter;Piotr Rutkowski

  • Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma

    Keith T. Flaherty;Caroline Robert;Peter Hersey;Paul Nathan

  • Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

    Dirk Schadendorf;F. Stephen Hodi;Caroline Robert;Jeffrey S. Weber

  • Immune-related adverse events with immune checkpoint blockade: a comprehensive review

    J.M. Michot;C. Bigenwald;S. Champiat;M. Collins

  • Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    J. B. A. G. Haanen;F. Carbonnel;C. Robert;K. M. Kerr

  • Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group

    K T Flaherty;C Robert;P Hersey;P Nathan;P Nathan

  • Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trial

    Caroline Robert;Antoni Ribas;Jedd D. Wolchok;F. Stephen Hodi

  • Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma

    G.V. Long;D. Stroyakovskiy;H. Gogas;E. Levchenko

  • Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

    Alexander M.M. Eggermont;Christian U. Blank;Mario Mandala;Georgina V. Long

  • Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

    Antoni Ribas;Igor Puzanov;Reinhard Dummer;Dirk Schadendorf

  • Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

    Georgina V. Long;Georgina V. Long;Daniil Stroyakovskiy;Helen Gogas;Evgeny Levchenko

Frequent Co-Authors

Dirk Schadendorf
Dirk Schadendorf University of Duisburg-Essen
Georgina V. Long
Georgina V. Long University of Sydney
Alexander M.M. Eggermont
Alexander M.M. Eggermont Institut Gustave Roussy
Antoni Ribas
Antoni Ribas University of California, Los Angeles
Reinhard Dummer
Reinhard Dummer University of Zurich
Paolo A. Ascierto
Paolo A. Ascierto National Institutes of Health
James Larkin
James Larkin Royal Marsden NHS Foundation Trust
Axel Hauschild
Axel Hauschild Kiel University
Richard F. Kefford
Richard F. Kefford Macquarie University
Omid Hamid
Omid Hamid Cedars-Sinai Medical Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re interested in healthcare but not sure that the traditional path to becoming a physician is right for you, a range of related online degrees and career pathways exist. These programs offer more flexibility and often quicker entry into the medical field, with in-demand roles and strong job growth.

For example, if you’re looking to work closely with medications and help improve patient outcomes, consider pharmacy school online. Pharmacy programs focus on preparing students for clinical and retail pharmacy roles.

Technology-minded students might opt for him programs, developing skills to manage and secure patient data. Alternatively, medical billing and coding classes online train you for behind-the-scenes roles that keep medical practices running smoothly.

For those interested in advanced nursing careers, cheapest fnp programs online allow you to become a Family Nurse Practitioner with more affordable tuition and the flexibility of distance learning.

Each of these options helps you advance your healthcare career on your own schedule, opening doors to vital roles in the medical field beyond traditional medicine.

Best Scientists Citing Caroline Robert

Trending Scientists

Recently Published Articles